Looking back at how children in China with Ph+ ALL were diagnosed and treated
Reviews past records of children in China with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
Key facts
- Where
- Hangzhou, ChinaSee the site
Where in China
- The Children's Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Children's Hospital of Zhejiang University School of Medicine
- Trial code
- NCT07813208
- Record updated
- 10 September 2026
- Original description
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.Read full original descriptionShow less
Real-world Investigation of Diagnosis, Treatment, and Survival Status of Children With Ph+ ALL in China
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.
Inclusion: Age at diagnosis ranging from 1 month to 18 years; Positive for the BCR::ABL fusion gene; Serial quantitative MRD testing was routinely performed using multiparameter flow cytometry (MFC) and PCR (qRT-PCR or ddPCR) during treatment, with samples collected for both assays at identical time points; Standardized TKI therapy (imatinib, dasatinib, or other TKIs) was administered.
Exclusion: Irregular treatment not administered in accordance with the chemotherapy protocol; Previous or concurrent other malignancies; Failure to receive standardized TKI therapy due to intolerance to TKIs, contraindications to TKI treatment, or other relevant factors; Mixed-phenotype acute leukemia.